# BMT CTN 0901: HCP commentary report

> 91 verified statements (40 from clinicians verified by NPI or staff page) from 23 commentary sources · 6 findings · updated Oct 31, 2026

## Report

- Trial: A Randomized, Multi-Center, Phase III Study of Allogeneic Stem Cell Transplantation Comparing Regimen Intensity in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia (BMT CTN #0901)
- NCT ID: NCT01339910
- Registry: https://clinicaltrials.gov/study/NCT01339910
- Sponsor: Medical College of Wisconsin
- Phase: Phase 3
- Status: Terminated
- Drugs tested: fludarabine plus busulfan; fludarabine plus melphalan
- Indication: acute myeloid leukemia or myelodysplastic syndrome
- Version: v1.0.0, edition 1
- Accepted: 2026-10-31
- Last checked: 2026-10-31
- Release hash: f5ae87d63678b5a7e28963ca8c6b546e9d55fffe990f89489fe71f1033d8c6f9

## Counts

- HCP commentary sources screened: 42
- Sources cited by verified statements: 27
- Verified statements: 91
- From speakers with a confirmed clinical role (verified by the NPI registry or their own institution's staff page): 40
- Findings: 6
- Named people in screened sources (unnamed speakers and accounts not counted): 30
- Voices cited: 30
- Cited voices identity-verified: 24
- Organisational or shared accounts (not counted as people): 1

Counts describe the retained sources. They do not estimate how many HCPs hold a view.

## Abstract

BMT CTN 0901 compares myeloablative with reduced-intensity conditioning before donor transplantation, asking which improves survival in adults with AML or MDS. Commentary comes from X posts, a podcast and YouTube interviews, including medical oncologists with confirmed clinical roles. The discussion turns on when fitness supports myeloablative conditioning in older patients, unresolved questions about MRD assays for intensity selection, and disagreement over delaying transplantation to clear residual disease.

## Open Medical Affairs question

How should Medical Affairs distinguish evidence for an MRD-informed conditioning choice from evidence for delaying transplantation to clear MRD, while keeping fitness, readiness and access explicit?

Raised by the leading finding. The report shows what clinicians said and the sources behind it; it does not settle the question.

## Findings (titles)

- F1. Better outcomes with MRD negativity do not establish that delaying transplantation to clear MRD helps
- F2. The preference for MAC is conditional on fitness, with explicit concern about overextension to older patients
- F3. MRD-dependent intensity choices attract interest, but the statements do not support blanket equivalence
- F4. MRD assessment is valued, while assay comparability and the evidence needed to act remain unsettled
- F5. Endpoint choice, statistical power and regimen classification complicate reconciliation across studies
- F6. Regimen-level toxicity, organ function and post-transplant support qualify the intensity decision

## What sits behind each finding

Counts describe what the report retained, not how many clinicians hold a view. A statement can support more than one finding.

| Finding | Statements | Passages | Sources | Named voices | Counterview | Limitations |
| --- | ---: | ---: | ---: | ---: | --- | ---: |
| F1 | 10 | 10 | 1 | 8 | recorded | 3 |
| F2 | 24 | 18 | 12 | 14 | recorded | 3 |
| F3 | 13 | 10 | 6 | 7 | recorded | 3 |
| F4 | 13 | 7 | 4 | 4 | none recorded | 3 |
| F5 | 16 | 10 | 8 | 8 | recorded | 3 |
| F6 | 15 | 6 | 4 | 3 | recorded | 4 |

### What the statements are

| Finding | Views | Questions and uncertainty | Clinical experience | Comparisons | Restated results and context | Passages supporting | Passages giving context | Sources by kind | Feeds the Medical Affairs question |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | --- | --- |
| F1 | 6 | 2 | 1 | 1 | 0 | 10 | 0 | 1 post or article | yes |
| F2 | 19 | 1 | 1 | 0 | 3 | 26 | 2 | 10 posts and articles, 1 podcast or video, 1 publication | yes |
| F3 | 7 | 3 | 0 | 0 | 3 | 13 | 2 | 4 posts and articles, 2 podcasts and video | yes |
| F4 | 4 | 3 | 2 | 0 | 4 | 15 | 0 | 1 post or article, 3 podcasts and video | yes |
| F5 | 6 | 0 | 1 | 3 | 6 | 17 | 0 | 5 posts and articles, 2 podcasts and video, 1 publication | yes |
| F6 | 7 | 0 | 0 | 2 | 6 | 15 | 0 | 2 posts and articles, 2 podcasts and video | yes |

### Trial dimensions

- Primary endpoint: Percentage of Participants With Overall Survival (OS): F2 (3 shared claims), F3 (2 shared claims), F5 (2 shared claims), F6 (1 shared claims)
- Secondary endpoints: F2 (6 shared claims), F5 (1 shared claims), F6 (4 shared claims)
- Population and setting: F2 (15 shared claims), F3 (2 shared claims), F4 (1 shared claims), F5 (2 shared claims), F6 (5 shared claims)
- The comparison: F1 (3 shared claims), F2 (13 shared claims), F3 (6 shared claims), F5 (5 shared claims), F6 (8 shared claims)
- Safety and tolerability: F2 (8 shared claims), F6 (9 shared claims)
- Design and conduct: F3 (1 shared claims), F4 (3 shared claims), F5 (10 shared claims)

## Sample findings

Paraphrased; the full report links each statement to its source.

### F5. Endpoint choice, statistical power and regimen classification complicate reconciliation across studies

An X post asks how to reconcile long-term findings from another AML conditioning study with BMT CTN 0901.

Source: X thread, 2018-03-15.

### F4. MRD assessment is valued, while assay comparability and the evidence needed to act remain unsettled

A YouTube interview explores whether a laboratory analysis added to BMT CTN 0901 could identify patients at higher relapse risk after reduced-intensity transplantation.

Source: YouTube video, 2019-07-16.

## What's inside

| Section | Items | Access |
| --- | ---: | --- |
| Findings with interpretation, counterviews and limits | 6 | Titles free |
| Detailed analysis | 7 sections | Paid |
| Verified statements with short source quotes and links | 91 | Paid |
| Trial aspects mapped | 11 | Free |
| Sources with links | 27 | Counts free |
| Speaker attribution for cited voices | 30 | Paid |

## Trial aspects

11 discussed · 0 no commentary found · 0 assessment incomplete.

| Aspect | Coverage | Statements | Sources |
| --- | --- | ---: | ---: |
| Primary endpoint: Percentage of Participants With Overall Survival (OS) | discussed | 7 | 4 |
| Secondary endpoints | discussed | 9 | 5 |
| Population and setting | discussed | 20 | 10 |
| The comparison | discussed | 28 | 13 |
| Safety and tolerability | discussed | 15 | 6 |
| Design and conduct | discussed | 12 | 6 |
| MRD-dependent intensity selection and assay interpretation | discussed | 22 | 8 |
| Immediate allo versus additional MRD-directed treatment | discussed | 11 | 2 |
| RICMAC, German AML comparisons and broader intensity classification | discussed | 8 | 5 |
| Maintenance, surveillance and patient support around transplantation | discussed | 8 | 2 |
| Evidence awareness, historical availability and research priorities | discussed | 11 | 7 |

An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.

## Sources

| Channel | Screened | Cited |
| --- | ---: | ---: |
| X threads | 39 | 20 |
| YouTube | 2 | 2 |
| Podcasts | 1 | 1 |
| Registry (primary source, cited for context) | not screened | 3 |
| Publications (primary source, cited for context) | not screened | 1 |

- Screened window: 2015-02-12 to 2026-08-20
- Cited window: 2015-09-19 to 2026-08-20
- Retrieved: 2026-10-31

Screened sources were retrieved for this trial. Cited sources back at least one verified statement and include primary sources used for context.

## The trial

From ClinicalTrials.gov.

- Title: A Randomized, Multi-Center, Phase III Study of Allogeneic Stem Cell Transplantation Comparing Regimen Intensity in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia (BMT CTN #0901)
- Registry: NCT01339910 (https://clinicaltrials.gov/study/NCT01339910)
- Study IDs: BMTCTN0901 · U01HL069294 · U01HL069294-05 · BMT CTN 0901 (Blood and Marrow Transplant Clinical Trial Network) · 5U24CA076518
- Sponsor: Medical College of Wisconsin
- Collaborators: National Heart, Lung, and Blood Institute (NHLBI), National Cancer Institute (NCI), Blood and Marrow Transplant Clinical Trials Network, National Marrow Donor Program
- Design: Phase 3 · interventional, randomized, parallel, phase3
- Status: Terminated
- Enrollment: 272 (actual)
- Start: 2011-06 (actual)
- Primary completion: 2017-01-16 (actual)
- Primary endpoint: Percentage of Participants With Overall Survival (OS) (18 months post-randomization)
- Intervention: Fludarabine and Busulfan (drug)
- Intervention: Fludarabine and Melphalan (drug)
- Intervention: Busulfan and Fludarabine (drug)
- Intervention: Busulfan and Cyclophosphamide (drug)
- Intervention: Cyclophosphamide and Total Body Irradiation (drug)

## Scope and limits

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

- Discussion that does not name the trial may be missing from this edition.
- Not yet captured in this edition: a question about transplant consolidation selection based on fitness, prior therapy, donor availability and residual disease testing.
- Not yet captured in this edition: a question about transplant conditioning selection in AML with prior refractory disease, persistent fungal lung cavities and a matched sibling donor.
- Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
- 29 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.
- This edition describes the sources reviewed, not the prevalence of views among HCPs or a professional consensus. Reposts and relayed presentations are not independent endorsements.
- Some potentially relevant passages were not fully assessed. Discussions without the trial's name or identifier, or using different transcriptions, may be missing.
- Full text was unavailable for two referenced publications. The primary results abstract was available, but detailed long-term and MRD interpretations here rely substantially on attributed commentary.
- Several brief replies lack the proposition or answer option needed to determine a specific clinical recommendation.
- Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.
- The a YouTube channel interview's spoken passages cannot be assigned to a named person from the available evidence.
- The statements come from different dates and clinical exchanges. Their order does not establish a change of mind, and historical statements about unavailable evidence are not current statements of absence.
- Only some interventions were checked for regulatory information, and exact combination labels were not located. No conclusion about regulatory status or absence of an applicable label can be drawn.

How reports are built and checked: https://www.erudio.com/methods

## Editions and corrections

- v1.0.0, accepted 2026-10-31: current edition

Last checked for new commentary 2026-10-31. No corrections. Versions follow semver: a new or changed finding is a minor version, more evidence without a material change is a patch.

## Offer

- Size: Focused (91 verified statements)
- Current edition: $750. A purchase starts a check for new commentary and any newer edition follows at no charge
- 3 months of weekly updates: $1,300
- 6 months of weekly updates: $1,900
- 12 months of weekly updates: $2,600
- Optional identity linkages (12-month updates only, product updates-12-identities; speakers are named and described in every report): NPI and other verified IDs at $15 per identity-verified person in the edition at purchase (24 now), at most $750; people verified later in the term at no charge
- Pricing: https://www.erudio.com/pricing
- Buy now (card, through Stripe): https://www.erudio.com/reports/bmt-ctn-0901-nct01339910
- Agents: POST https://www.erudio.com/api/orders with {"report": "bmt-ctn-0901-nct01339910", "product": "edition" | "updates-3" | "updates-6" | "updates-12" | "updates-12-identities", "buyer_email": "...", "licence_key": "<your key, if you hold one>"}; it returns a payment link for your user (and a pay_url your own MPP or x402 payment client can pay over HTTP 402, when offered), and once paid the status_url returns your license key. Send the same key with every later order so all reports sit on one key. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST https://www.erudio.com/api/keys/recover) sends it again
- Talk to Audun Utengen and Tom Lee (invoice, PO, questions): https://www.erudio.com/contact?report=bmt-ctn-0901-01339910

## Cite

Erudio Health. BMT CTN 0901 (NCT01339910): HCP commentary report. Edition 1, v1.0.0. Accepted Oct 31, 2026. https://www.erudio.com/reports/bmt-ctn-0901-nct01339910

## Machine access

- JSON: https://www.erudio.com/reports/bmt-ctn-0901-nct01339910.json
- Markdown: https://www.erudio.com/reports/bmt-ctn-0901-nct01339910.md
- MCP, no sign-in: https://mcp.erudio.com/free, tool `get_report_card` with `{"slug": "bmt-ctn-0901-01339910"}`